1. Neurosteroids: the concept {#sec1}
=============================

It is well recognized that the cytosolic steroid hormone receptors, after binding with their ligand, translocate to the nucleus where they may alter gene expression via chromatin remodeling mechanisms ([@bib29]). Over the past 30 years, direct and rapid membrane actions of steroid hormones and their metabolites have also been demonstrated. One of the clearest examples of a rapid, non-genomic steroid action on a membrane receptor is the demonstration that the natural metabolites of progesterone and deoxycorticosterone (DOC); i.e., allopregnanolone and allotetrahydroDOC (THDOC), respectively, exert their main actions as powerful endogenous positive allosteric modulators of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) at both synaptic and extrasynaptic GABA~A~ receptors ([@bib26], [@bib17], [@bib43]; [@bib47]; [@bib5]). These steroids are termed neurosteroids and sometimes referred to as neuroactive steroids. As proposed by Baulieu, the term *neurosteroid* "applies to those steroids that are both synthesized in the nervous system, either *de novo* from cholesterol or from steroid hormone precursors like progesterone that accumulate in the nervous system" ([@bib47]). *Neuroactive steroids*, a term coined by [@bib36] refers to "any natural or synthetic steroid that rapidly alters neuronal excitability via non-genomic mechanisms."

In a historical perspective, herein, we review findings of seminal preclinical and clinical studies that recently have led to the demonstration that treatment with allopregnanolone (i.e., brexanolone, marketed as Zulresso™) can dramatically and rapidly improve symptoms in many women with postpartum depression (PPD).

The authors dedicate this article to the memory of Erminio Costa, a true pioneer in the field of neurosteroids and GABA~A~ receptors, our scientific mentor, collaborator and friend.

2. The brain as a neuroendocrine organ {#sec2}
======================================

To answer the question of whether allopregnanolone is synthesized in brain, [@bib45] using a sensitive radioimmunoassay measured allopregnanolone in rat brain and serum both before and following swim stress. Levels of allopregnanolone increased in brain and serum after acute swim stress and demonstrable brain levels persisted even after adrenalectomy and ovariectomy ([@bib45]). Subsequently [@bib6] measured allopregnanolone, 5α-dihydro-progesterone (5α-DHP), and progesterone in brain, plasma and liver of control and adrenalectomized mice using gas chromatography-mass spectrometry (GC/MS) with unsurpassed molecular selectivity and specificity ([@bib55]; [@bib38]; for an update, see [@bib21]). In this study, allopregnanolone remained elevated in brain also 15 days after adrenalectomy. At this time, the level of progesterone was greatly reduced. These two studies suggest that the allopregnanolone present in brain is synthesized, at least in part, independently of the control of the pituitary on peripheral endocrine tissues ([@bib46]; [@bib6]).

3. Allopregnanolone: biosynthesis and metabolism in mammalian brain {#sec3}
===================================================================

The biosynthesis of allopregnanolone starts from cholesterol ([Fig. 1](#fig1){ref-type="fig"}). To this end, it became essential to identify the location of the metabolic steps and enzymes that control the recruitment and metabolism of cholesterol to a specific small pool that can be used for progesterone and allopregnanolone biosynthesis. The first step of neurosteroid biosynthesis is the transport of cholesterol from the outer into the inner mitochondrial membrane primarily in glial cells. Costa and colleagues discovered that the transport of cholesterol to the inner mitochondrial membrane is dependent on the presence and activation of a small 18 kD protein named "translocator protein" (TSPO), initially known as the peripheral benzodiazepine receptor ([@bib54]; [@bib34]) because of its ability to bind benzodiazepines and an endogenous peptide called diazepam binding inhibitor (DBI) ([@bib9]). TSPO is expressed in glial cells and not in neurons and when occupied by 2-aryl-indole-acetamide derivatives ([@bib48]), or by N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenylpurin-9-yl)acetamide (AC-5216, XBD173) ([@bib50]) elicits a non-sedative, anxiolytic, and antipanic action via activation of neurosteroid biosynthesis and enhancement of GABA~A~ receptor activity. Inside mitochondria, cholesterol is initially metabolized to pregnenolone by the action of P450~scc~ and to progesterone by 3β-hydroxysteroid dehydrogenase (3β-HSD).Fig. 1**Biosynthesis of allopregnanolone**.Neurons can synthesize allopregnanolone *de novo* starting from cholesterol, which is recruited and translocated into the inner mitochondrial membrane preferentially in glial cells. Here, P450SCC metabolizes cholesterol into pregnenolone, the precursor of all neurosteroids. Pregnenolone is then taken up from neurons and is further metabolized into progesterone by 3β-HSD and progesterone can be further converted by the rate-limiting step enzyme, 5α-reductase type I into 5α-dihydroprogesterone (5α-pregnan-3,20-dione, 5α-DHP). Finally, 5α-DHP can be reduced into allopregnanolone (3α-hydroxy-5α-pregnan-20-one or 3α,5α-tetrahydroprogesterone) by the 3α-hydroxysteroid dehydrogenase (3α-HSD) enzyme. Allopregnanolone can eventually be reconverted into 5α-DHP.Fig. 1

Using in situ hybridization and immunohistochemistry it was possible to define the neuronal and glial expression and location of the enzymes required for allopregnanolone biosynthesis in rodents ([@bib2]). Allopregnanolone and THDOC are synthesized in the brain from progesterone or deoxycorticosterone, respectively, by the sequential action of two enzymes: 5α-reductase (5α-R) type I and 3α-hydroxysteroid dehydrogenase (3α-HSD). These studies demonstrated that 5α-R type I and 3α-HSD, the rate-limiting step enzymes for allopregnanolone biosynthesis ([@bib11]), colocalize in cortical, hippocampal, basolateral amygdala and olfactory bulb glutamatergic principal neurons and in some output neurons of the lateral amygdala and thalamus ([@bib2], [@bib3]). Neither 5α-R type I nor 3α-HSD mRNAs, however, are expressed in S100β- or glial fibrillary acidic protein-positive glial cells. Using glutamic acid decarboxylase 67/65 antibodies as a marker for GABAergic neurons, it appears that there is no detectable 5α-R type I and 3α-HSD in cortical and hippocampal GABAergic interneurons ([@bib2]). However, 5α-R type I and 3α-HSD are expressed in GABAergic output neurons, such as striatal neurons, reticular thalamic nucleus, and cerebellar Purkinje neurons ([@bib3]). A similar distribution and cellular location of these neurosteroidogenic enzymes was observed in human brain ([@bib1]). More recently, using a specific antibody against allopregnanolone, Morrow and colleagues confirmed the neuronal localization of this neurosteroid in the rodent brain ([@bib8]).

Taken together, these data suggest that allopregnanolone and THDOC, which can be synthesized in principal output neurons, modulate GABA\'s action at GABA~A~ receptors, either in an autocrine or paracrine manner or by accessing GABA~A~ receptor intracellular sites through lateral diffusion in the neuronal membrane ([@bib42]). In this regard, it is also remarkable that TSPO is present in glial cells and not in neurons ([@bib35]).

4. Allopregnanolone and GABA~A~ receptor modulation {#sec4}
===================================================

Allopregnanolone acts at low nanomolar concentrations as an endogenous modulator of GABA action at GABA~A~ receptors ([@bib26]; [@bib43]; [@bib36]; [@bib20]; [@bib12]). Electrophysiological studies with different combinations of transfected GABA~A~ receptor subunits in 293 kidney tumor cell lines, as well as native GABA~A~ receptors in cerebellar granule cells indicate that allopregnanolone and its congeners bind to specific sites on GABA~A~ receptors ([@bib33], [@bib32]; [@bib18]), that differ from those at which the benzodiazepines bind ([@bib43], [@bib44]; [@bib20]; [@bib58]). For example, benzodiazepines increase the potency of GABA only when α1, α2, or α3 subunits are assembled with β and γ~2~ subunits in the canonical pentameric structure of GABA~A~ receptors ([@bib52]). In contrast, allopregnanolone will regulate the function of GABA~A~ receptors containing the δ subunit in place of the γ subunit ([@bib32]; [@bib53]; [@bib4]; [@bib43]). These δ subunit-containing GABA~A~ receptors are presumably extrasynaptic and extremely sensitive to GABA and allopregnanolone but relatively insensitive to the action of benzodiazepines ([@bib25]; [@bib24]; reviewed in [@bib22]). By this mechanism, endogenously produced allopregnanolone plays a pivotal neurophysiological role in the fine-tuning of GABA~A~ receptors to GABAmimetic drugs, agonists and allosteric modulators, and may as well regulate emotional behavior in response to stress ([@bib38]; [@bib15]).

5. Allopregnanolone and the pathophysiology of depression {#sec5}
=========================================================

Decreases in the brain levels of allopregnanolone during the postpartum period, or during exposure to protracted severe stress appear to play a crucial role in controlling neuronal excitability via local modulation of extrasynaptic GABA~A~ receptors. Marked fluctuations in both the brain and blood concentrations of allopregnanolone strongly correlate with fluctuations of GABA~A~ receptor function and plasticity. In addition to pregnancy (mentioned above) there are several other interesting pathophysiological conditions that alter the function and plasticity of GABA~A~ receptors by modifying the brain level of allopregnanolone. They include the postpartum period in human ([@bib23]), mice and rats ([@bib7]), social isolation stress in mice ([@bib27]; [@bib40]), and major depression in humans ([@bib56]; [@bib49]).

The increase in brain levels of allopregnanolone during pregnancy and the sudden decrease immediately following parturition have been shown to alter the expression/function of specific GABA~A~ subunits in the cortico-limbic structures ([@bib7]; see also [@bib14]). These data suggest that alterations in GABA~A~ receptor expression, especially extrasynaptic GABA~A~ receptors, may be related to psychiatric disorders associated with changes in neurosteroid levels, i.e., those associated with pregnancy and the menstrual cycle in women. These findings could help to provide potential new treatments for these disabling hormone-dependent syndromes.

The discovery that allopregnanolone and THDOC elicit marked anxiolytic and anti-stress effects and selectively facilitate GABA-mediated neurotransmission ([@bib10]; [@bib28]; [@bib13]; [@bib59]), has also provided new perspectives for our understanding of the pathophysiology and neurobiology of stress and anxiety. Protracted exposure of mice to the stress of social isolation results in a marked decrease of 5α-R type I and a 50% decrease in brain allopregnanolone levels ([@bib27]; and [@bib15]; [@bib37]). Treatment with the antidepressant fluoxetine normalizes this stress-induced decrease in allopregnanolone ([@bib40]; reviewed in 2006). The exact mechanism responsible for the decreased brain allopregnanolone levels in the brain of socially isolated mice is not known but it is possible that it involves epigenetic regulation of the genes encoding one or more of the enzymes involved in neurosteroid biosynthesis or metabolism (discussed in [@bib42]). Interestingly, in socially isolated mice, fluoxetine and analogs stereospecifically normalize the decrease of allopregnanolone biosynthesis and improve behavioral dysfunction by a mechanism that is independent of 5-HT reuptake inhibition ([@bib40], [@bib41]).

The evidence that downregulation of allopregnanolone biosynthesis in brain results in downregulation of GABA receptor-mediated tonic inhibition in patients with major depression and that this can be reversed by indirectly increasing the brain content of allopregnanolone with fluoxetine, supports the view that depression, stress, neurosteroids, and the function of GABA~A~ receptors are intimately related.

Fluoxetine or paroxetine, two selective serotonin reuptake inhibitors (SSRIs), when administered to rats, increase the brain content of allopregnanolone without altering the brain content of other neurosteroids ([@bib55]). As mentioned above allopregnanolone binds with high affinity to δ subunit-containing GABA~A~ receptor subtype and augments the action of GABA at these receptors, which control tonic inhibition in the brain ([@bib43]; [@bib31]). We hypothesized that the increased brain content of allopregnanolone induced by treatment with SSRIs could contribute to alleviating the symptoms of anxiety and depression associated with major depression ([@bib16]). Further, we measured allopregnanolone content in the cerebrospinal fluid (CSF) before and 8--10 weeks after treatment with fluoxetine or fluvoxamine in 15 patients with major depression ([@bib56]). The concentration of allopregnanolone (approximately 40 fmol/ml in each CSF fraction of three control subjects) was about 60% lower in patients with major depression compared to matched non-depressed controls. Moreover, in the same patients, fluoxetine or fluvoxamine treatment normalized CSF allopregnanolone concentrations. Importantly, a statistically significant correlation (r = 0.58; P \< 0.023; n = 15) between improvement in depressive symptoms (Hamilton Rating Scale for Depression scores) and the increase in CSF allopregnanolone following fluoxetine or fluvoxamine treatment was observed. The CSF concentration of pregnenolone and progesterone remained unaltered after treatment and did not correlate with the SSRI-induced increase of CSF allopregnanolone or improvement in depression ([@bib56]). The normalization of CSF allopregnanolone concentration in depressed patients could at least in part mediate some of the anxiolytic and antidepressant actions of fluoxetine or fluvoxamine indirectly via their effects on neurosteroid biosynthesis and thus the positive allosteric modulation of GABA~A~ receptors (discussed in [@bib16]; [@bib41]). New molecules that stimulate TSPO and elevate allopregnanolone levels, including XBD173 and [etifoxine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5468){#intref0010} induce anxiolytic effects in animal models and anxious patients ([@bib50], [@bib60]; [@bib51]).

6. Allopregnanolone and postpartum depression {#sec6}
=============================================

PPD is the most common complication of pregnancy and affects between 10 and 20% of women during or just following childbirth. PPD negatively affects not only the suffering mother but her entire family and it has been estimated that 20% of postpartum deaths are due to suicide secondary to PPD. Given the early data demonstrating that serum and brain levels of progesterone and allopregnanolone rise during pregnancy, reaching a peak in the third trimester, and then fall precipitously following parturition ([@bib23]), it has long been speculated that PPD might in part be due to these rapid changes in neurosteroid levels that occur during pregnancy and the immediate postpartum period. While this area has been comprehensively reviewed by [@bib57], we will highlight just a few of the salient data that strongly implicate this neuroactive steroid as the trigger for PPD (at least in many women), and which has led directly to the successful development of a proprietary formulation of allopregnanolone as the first effective treatment for PPD ([@bib30]).

While decreased CSF levels of allopregnanolone have been implicated in major depression as reviewed above and while some groups have reported lower and even higher serum allopregnanolone levels during pregnancy in women who subsequently develop PPD, the relationship between serum allopregnanolone levels and PPD *per se* has been inconsistent at best across studies and thus it is difficult to assign a specific role for alterations in allopregnanolone levels in the etiology or pathophysiology of PPD. However, more recent animal models of PPD have been informative and strongly suggest that the adaptive changes in GABA~A~ receptor expression that occur in response to increased brain levels of allopregnanolone during pregnancy and specifically a downregulation of extrasynaptic GABA~A~ receptors that control tonic inhibition may underlie the pathophysiology of PPD. Mice that lack or have diminished numbers of δ subunit-containing extrasynaptic GABA~A~ receptors develop depression-like behaviors and marked deficits in maternal care mimicking PPD. Using this animal model of PPD, [@bib25] demonstrated that drugs that enhance extrasynaptic GABA~A~ receptor-mediated tonic inhibition were effective at improving these PPD-like behaviors. These data, together with all of the early work implicating allopregnanolone and GABA~A~ receptors in depression, anxiety and sleep disorders (all prominent symptoms of PPD) led to the seminal clinical studies by scientists and clinicians at Sage Therapeutics which have demonstrated that treatment with allopregnanolone (i.e., brexanolone) can dramatically improve the signs/symptoms of PPD in many women.

The development of allopregnanolone for PPD began with a small open label proof-of-concept study by Meltzer-Brody and colleagues and progressed sequentially into formal double blind and placebo-controlled phase 2 and phase 3 clinical trials ([@bib19]; [@bib30]). Each of these studies showed that intravenous infusion of allopregnanolone/brexanolone at levels mimicking those that occurs during late pregnancy resulted in marked and rapid improvement in measures of depression, anxiety and sleep in the majority (but not all) of women with PPD. Most of these patients had moderate or severe PPD that did not respond adequately to other traditional antidepressant drugs. Importantly, the therapeutic benefit of brexanolone infusion over 60 h appeared to be quite durable as patients remained euthymic or free of depressive symptoms 30 days following treatment ([@bib19]; [@bib30]). Given the efficacy of brexanolone in improving the debilitating symptoms of PPD, its relative safety profile and thus very positive benefit/risk ratio, brexanolone was approved by the FDA on March 19, 2019 and is now marketed in the U.S., as Zulresso™.

Conclusions {#sec7}
===========

The discovery of the potent actions of the neurosteroid, allopregnanolone on GABA~A~ receptors has catalyzed much good work by scientists across the globe leading to the successful development of the first targeted treatment for PPD. In our view, this represents one of the best examples of rationale drug discovery in neuropsychiatry, based on solid scientific evidence and clinical data (see [Fig. 2](#fig2){ref-type="fig"} for a timeline of major neuroactive steroids discoveries leading to the development of brexanolone for PPD). Hopefully, other effective novel neuroactive steroid medicines for treating serious mood and anxiety disorders will follow.Fig. 2Timeline of Major Neuroactive Steroid Discoveries leading to the Development of Brexanolone for Post-Partum Depression.Fig. 2
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